Organoid Clinical Trial against CoVID-19, page-151

This just to try to legitimise my thoughts on monepantel being trialed in the treatment of Covid 19 by Eli Lilly from the information that is at hand. And of course it is the way it seems to me. You can make your own mind up.
In this first link at 1:10:03 When Professor Marc Pellerini was asked about PAA and Covid 19 he said it was more likely to be an international trial
https://app.sli.do/event/m7unmljl/live/polls

In the next link Dr Aston was asked about Eli Lilly and human cancer, He volunteered an association, maybe uninteionsionaly, to Covid19 at at 47:15
https://app.sli.do/event/m7unmljl/live/polls

In the same link Dr Aston was asked another question about Covid 19 at 45:42. Later in the reply he said that PAA would need an "Agreement" or to my way of thinking " Permission" from the patent holders to trial Monepantal for Covid 19 to be used in such a trial 46:15.

So all this leads me back to Doh ( Mary Poppins) . International involvement that is .Anybody that has had an association with PAA for any length of time knows that Elenco hold the patent for MPL at the moment,and that Elenco are a spin of company of Eli Lilly. Our board have ties with Eli Lilly. Epichem have ties with Eli Lilly. TEST TEST ONE TWO TWO TWO. Can you hear me up the back!!!!!!!!!!!!

Well that brings us to the next link. This will be the third time I have posted it.

https://app.sli.do/event/m7unmljl/live/polls
Her are a couple of extracts from it

Given by infusion, monoclonal antibodies are similar to the convalescent plasma treatments harvested from blood that's been donated by people who have already recovered from COVID-19.
But unlike convalescent plasma, which relies on blood donors, monoclonal antibodies are manufactured as a pharmaceutical product, meaning they should be much easier to produce in large quantities.

" My thoughts,You can grind out monoclonal antibodies like panadol etc. "

Monoclonal antibodies are promising because they should, in theory, block the virus from entering the cells, Ellerin explained. "The virus wants to enter the cell, so this monoclonal antibody blocks that molecular doorway and doesn't allow the virus to enter the cell."

"My thoughts, that is the way MPL works."

But Eli Lilly calls its study the "first of its kind."

At least, said Ellerin, "That's the hope."

So let's look at what Eli Lilly are saying baring in mind they are one of the big carhoners.
FIRST OF ITS KIND.
And Shirt if that aint Monepantel Please explain